STEAP3 and hepatocellular carcinoma: The mean disease-free survival time for HCC patients with high nuclear expression of STEAP3 was 29.5 months compared with a survival time of 46.4 months for patients with low nuclear expression of STEAP3 (p < 0.01, log-rank test, Table 2).